Verification evidence is still being completed.
PDF / print export
Aranda Pharma Ltd.
Kuopio, Finland
- Verified lead
- Mika Kayhko
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- Non-Steroidal Androgen-Receptor Inhibitors, Topical Dermatology, and Hair Loss and Acne Programs
- Review cycle
- 24 April 2026
- Full address
- Microkatu 1, P.O. Box 1199, FI-70211 Kuopio, Finland
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Aranda Pharma team page naming Mika Kayhko as Chief Executive Officer.
- Editorial note
- Kuopio preclinical dermatology pharma SME with named CEO, medicinal-chemistry pipeline for hair loss and acne, and outsourced GLP safety studies.
Non-Steroidal Androgen-Receptor Inhibitors, Topical Dermatology, and Hair Loss and Acne Programs
Public CEO disclosure on company site, Preclinical pipeline documentation, Partner GLP coverage
Kuopio preclinical dermatology pharma SME with named CEO, medicinal-chemistry pipeline for hair loss and acne, and outsourced GLP safety studies.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Kuopio, Finland
Aranda Pharma Ltd.
Non-Steroidal Androgen-Receptor Inhibitors, Topical Dermatology, and Hair Loss and Acne Programs · Preclinical small-molecule development
Kuopio preclinical dermatology pharma SME with named CEO, medicinal-chemistry pipeline for hair loss and acne, and outsourced GLP safety studies.
- Lead
- Mika Kayhko (verified ↗)
- Address
- Microkatu 1, P.O. Box 1199, FI-70211 Kuopio, Finland (source ↗)
- Compliance
- Partner GLP coverage
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- Preclinical small-molecule development
- Capabilities
- Medicinal Chemistry Drug Discovery · Topical Androgen-Receptor Inhibitor Programs · IND-Enabling Studies
- Founded
- 2018
- Headcount
- 1-10
Clinical profileSTATUS: VERIFIED APRIL 2026
Mika Kayhko
Chief Executive Officer
Full addressMicrokatu 1, P.O. Box 1199, FI-70211 Kuopio, Finland
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Preclinical small-molecule development
Kuopio, Finland. Non-Steroidal Androgen-Receptor Inhibitors, Topical Dermatology, and Hair Loss and Acne Programs. Review completed on 24 Apr 2026.
Fimea and EMA for future clinical oversight
Public CEO disclosure on company site, Preclinical pipeline documentation, Partner GLP coverage
Non-Steroidal Androgen-Receptor Inhibitors, Topical Dermatology, and Hair Loss and Acne Programs
Kuopio preclinical dermatology pharma SME with named CEO, medicinal-chemistry pipeline for hair loss and acne, and outsourced GLP safety studies.
Editorial note
Aranda Pharma is a Kuopio preclinical-stage pharma SME with a named CEO since October 2023, documented medicinal-chemistry pipeline for androgenetic alopecia and acne, and outsourced GLP safety testing.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Medicinal Chemistry Drug Discovery
Topical Androgen-Receptor Inhibitor Programs
IND-Enabling Studies
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Medicinal chemistry workflow
Preclinical dermatology models
Partner GLP safety studies
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Aranda Pharma Ltd. located?
- Aranda Pharma Ltd. operates from Microkatu 1, P.O. Box 1199, FI-70211 Kuopio, Finland, Kuopio, Finland.
- Who runs Aranda Pharma Ltd.?
- Aranda Pharma Ltd. is led by Mika Kayhko, Chief Executive Officer. Verified 24 Apr 2026.
- What certifications does Aranda Pharma Ltd. hold?
- Aranda Pharma Ltd. is documented under Partner GLP coverage.
- What does Aranda Pharma Ltd. do?
- Kuopio preclinical dermatology pharma SME with named CEO, medicinal-chemistry pipeline for hair loss and acne, and outsourced GLP safety studies. Core capabilities: Medicinal Chemistry Drug Discovery, Topical Androgen-Receptor Inhibitor Programs, IND-Enabling Studies.
Editorial context
Related technical briefs
Briefs that name Kuopio as a covered market or city.